Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order …

95 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Speak up against substandard and falsified medicines! The Fight the Fakes Alliance and its members work collectively to tackle the growing global burden of substandard and falsified medicines to safeguard public health and strengthen health systems.

Type: Startup Activities: deeptech

Pioneering rational design of drugs made of defined bacteria consortia that are essential dwellers of the gut ecosystem. The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Regulatory Medical Writing Your premium submission partner in bringing the right product, to the right patient, on time Accelerating Access to Treatments for Rare Diseases At the intersection of science and strategy, we support pharmaceutical companies, biotech, and CROs in bringing innovative therapies to market — especially in the challenging field of rare diseases. As a specialised regulatory medical writing and consulting agency, we provide expert guidance across the clinical development pathway. From early phase documentation to submissions for marketing authorisation, we turn complex science into meaningful communication that informs and inspires better healthcare decisions. With deep knowledge of regulatory …

71 similar entities Type: SMB Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Know your patient, know your drug Genialis is a precision oncology company helping the most promising molecules become life-saving medicines. We are creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. Data Fusion, Machine Learning, Biomedical Data Analysis, Omics Data Integration, …

103 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Data Analytics

Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and change how brain disorders are thought about and treated. Our mission is to pioneer solutions with the potential to deliver life-changing brain health medicines, so every person can thrive. Welcome To The Workplace With A Difference At Sage, we believe that life is more …

136 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Speeding up the research revolution with you. DNAsimple, now part of Joined Bio, continues its mission to make participant engagement simple, secure, and rewarding. Through Joined Bio, we enable researchers to access qualified participants, biospecimens, and real-world data quickly and ethically, accelerating discovery and improving lives, all from the comfort of home. Together, we are building a more connected and transparent research ecosystem that bridges people and science. Request a quote today: https://joined.bio/quote-request/ genetics, genomics, biobanking, genetic research, saliva , DNA, DNA sample, microbiome, donor compensation, DNAsimple, healthcare research, and personalized medicine

96 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

The company that believes everyone should benefit directly from compelling scientific research. Elysium Health’s mission is to solve the biggest challenges in health with science, to help people live healthier for longer. Elysium works directly with top scientists, clinicians and health professionals around the world to translate advances in science and technology into innovative health products that work. Our product development pipeline begins with research and development, continues with preclinical studies, and culminates with human clinical trials to demonstrate the safety and efficacy of products. Throughout this process, Elysium’s focus is to develop compounds found in nature that allow people …

52 similar entities Type: Startup Activities: biotech deeptech

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer …

115 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Improving life for cancer patients through transformative drugs Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share …

65 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

We Chase the Miracles of Science to Improve People’s Lives. Sanofi is an innovative, global biofarmaceutical company, which is guided by one goal, so that according to the slogan "We Chase the Miracles of Science to Improve People’s Lives", focusing on the power of science, change the world for the better. In 100 countries, the teams involved and talented work to change the face of medicine, making impossible possible. The company creates therapies and vaccines that save lives to millions of people around the world. We have a wide range of specialized medicinal products and services in many therapeutic areas …

77 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Powering researchers’ insights with innovative single cell, spatial biology, & in situ tools. 🧬🔬 Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team …

73 similar entities Type: SMB Activities: industry 4.0 it services Technologies: Synthetic Biology

LYMPHOGENiX is a leading company for lymphatic vessel regeneration research based in the UK and Japan operating globally LYMPHOGENiX is a UK-based biotechnology company focused on developing first-in-class therapeutics for infertility, leveraging a novel and underexplored biological system: the lymphatic vasculature. Infertility remains a major and growing global health challenge, affecting millions of individuals and couples worldwide. Despite advances in assisted reproductive technologies, implantation failure and poor endometrial receptivity continue to limit success rates. LYMPHOGENiX was founded to address this unmet need by targeting a fundamental but overlooked component of reproductive biology. Our core scientific insight is that lymphatic vessels …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerate drug time to market through real study traceability and unparalleled trial integrity At Verisian, we envision a world where groundbreaking treatments are judged using all available evidence and the best tools, where the science is transparent to companies, regulators, and patients alike, and where patients have access to the latest cutting-edge treatments as soon as possible. We’re building innovation for clinical research and public health authorities. While CDISC standards like SDTM and ADaM have brought standardization for clinical trial data, lengthy analysis and submission cycles remain just as increasing trial complexity presents substantial challenges in decision-making and the potential …

259 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Data Analytics

Developing mRNA vaccines and therapeutics In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company. This acquisition further accelerates Sanofi’s efforts to develop transformative vaccines and therapies using mRNA technology. It adds a critical pillar to the company’s mRNA Center of Excellence, which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We …

144 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Connecting the scienctific community and patient care to advance HCT and cellular therapies. Join our community! 🌎 EBMT is a non-profit medical and scientific organisation established in 1974. We host a unique patient registry providing a pool of data to perform studies and assess new trends in the field of HCT, cellular and gene therapies. We aim to be the connection between patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies. Our community of healthcare professionals is focused on innovation, research and the advancement of these fields to save and improve the lives of …

81 similar entities Type: SMB Activities: edtech Technologies: Synthetic Biology

Transform how you model human biology. Ricoh Biosciences is a global leader in biotechnology, headquartered in the Science + Technology Park at the Johns Hopkins Medical Campus in Baltimore, MD. Our mission is to advance science and medicine with fast, functional, and scalable induced pluripotent stem cell (iPSC) differentiation products and services. Our state-of-the-art, transcription-factor-based technology allows you to overcome the high cost and inefficiencies associated with lengthy cell differentiation periods. We empower research institutions, pharmaceutical organizations, and biomedical enterprises worldwide, even those with no previous iPSC experience, by increasing access to relevant cells for modeling human biology and accelerating …

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision Engineered Medicines to Silence Diseases Our 20-plus years of RNAi experience together with our validated mRNAi GOLDTM platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients …

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We are harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Driven by the heart We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease. For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Helping patients getting self-ownership over their genomic data THE HUMAN GENOME FOUNDATION IS A REGISTERED CHARITY (ANBI) COMMITTED TO AFFECTING LASTING CHANGE ON A GLOBAL LEVEL. The Global Human Genome Foundation has been founded in 2017 with a single purpose: to create a world where vital and live saving information is within reach of people who need it most. The founder experienced that there is more information about genomics to save lives. Hence our mission is to make this information available for all people. By building a future where all people have access to their genomic data and lifesaving knowledge. …

25 similar entities Type: Startup Activities: healthtech Technologies: Cybersecurity

Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. We are currently advancing a pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions. Our lead product candidate, apraglutide, is a second generation, potentially best-in-class, synthetic peptide analog of glucagon-like peptide-2, or GLP-2, that is being evaluated in two Phase 2 clinical trials for the treatment of patients with short bowel syndrome, or SBS, a malabsorption disorder caused …

110 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Driving immune-mediated therapeutic innovation for women. Freya Biosciences is a clinical-stage immunology company developing therapies treating inflammation and immune dysregulation in conditions that affect women. Freya is advancing a diversified pipeline, including two first-in-class Phase 2-ready assets for IVF-related embryo implantation failure and preterm birth. Freya’s science is powered by its DyscoverTM platform, a unique multi-omics data science platform built on a biobank of 1,000+ clinical samples derived from both observational and randomized, placebo controlled trials. This provides deep insights into disease pathway associated markers, allowing for de-risked target identification and patient stratification. Backed by a world-class team with a …

62 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Engineering the future of aging medicine. We are advancing small molecule therapeutics for age-related diseases. Our platform enables precise, dynamic control of biological targets and pathways, generating high-fidelity datasets that, combined with advanced AI, unlock systematic exploration of previously inaccessible chemical space. At its core are our ultra-large, in-house aging datasets, which provide a rich foundation for target identification and therapeutic discovery. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, rejuvenation, molecular biology, novel therapeutics, therapeutics, and small molecules

178 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity. Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio. Biotechnology, Ultra Sensitive Immunoassays, and research

203 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Apriori Bio is working to create a world where humanity is protected against viral threats. Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation, precision, and purpose - redefining infection diagnostics for better outcomes. At Noscendo, we save and improve lives by revolutionising infection diagnostics. Through our metagenomic technology DISQVER®, we empower clinicians to identify pathogens rapidly, precisely, and without assumptions — helping patients receive the right treatment at the right time. We believe in a future where infectious diseases no longer claim lives unnecessarily. Driven by our values, we act with openness and reliability, always put patients first, grow and empower each other, and innovate to elevate modern medicine. We take ownership — and deliver results that matter.

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reimagining ADCs. Tubulis is now part of Gilead Sciences. Gilead is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. For more information on Gilead, please visit www.gilead.com and follow @GileadSciences on LinkedIn for updates. Note: Comments on the Tubulis LinkedIn page are not actively monitored. Antibody Drug Conjugates, Targeted Therapy, Biotechnology, and Drug Development

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

For the love of the child. With the power of science. Vita 34 is the pioneer and market leader in cell banking in Europe. In over 28 years of company history, we have stored over a million cell preparations and supported the therapy of over 7,000 people. The FamiCord Group is on an exciting journey as we integrate several smaller European companies with decades of tradition and established local market positions into a strong international group. We want to continue our growth in the next few years by expanding our core business of stem cell storage from umbilical cord blood, …

78 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.” Through ongoing collaborations with world-leading academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed Therapeutics is establishing a growing pipeline of exciting drug candidates on a path to clinical and commercial success. Our mission is to positively impact human health by creating novel protein degradation therapeutics for the treatment of severe diseases for which health care professionals currently have limited options to offer to patients. Biotechnology, Biotherapeutics, Cell …

201 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to enable the promise of genomics to better human health. At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to …

104 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using …

240 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to the development of novel therapies to improve the lives of patients with respiratory disease Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. …

71 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

The Art of Glue Hunting A curious team of explorers, deeply rooted in science, and constantly on the lookout for a very particular novel drug modality. This is us – Proxygen. We hunt for glue degraders. They are the key to unlocking new treatments for patients. They revolutionize how we see and cure diseases.

139 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science of certainty Gubra is a biotech company built on three synergistic business units, Biotech, CRO Services, and Ventures, united by a commitment to scientific excellence, strong partnerships, and responsible impact. ESG principles are embedded in our business model, including Gubra Green, our subsidiary that allocates 10% of pre-tax profits to support a net-zero, nature-positive future. Founded in 2008, Gubra has grown from a metabolic research specialist into a diversified organization of more than 300 scientists and experts. Today, we advance proprietary therapeutic programs, deliver high-end preclinical research services to global partners, and create new drug discovery opportunities through agile …

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing cancer care through microbiome profiling 🦠 Discover your microbiome: www.mybioma.com Biome Diagnostics GmbH (BiomeDx®) is an Austria-based MedTech company driving precision medicine through pioneering microbiome-based technologies that transform cancer care. At the intersection of state-of-the-art DNA sequencing and advanced machine learning, BiomeDx® develops first-in-class solutions for routine clinical practice. In addition to the lifestyle product myBioma (www.mybioma.com) for end-customers, the company focuses on medically certified products in the fields of gut microbiome and cancer. With ISO 9001 and ISO 13485 certifications, BiomeDx® is the first microbiome company worldwide with dual ISO certification — reflecting our commitment to safety and …

79 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Multiorgan support for rare pediatric and acute liver diseases Versantis is a clinical-stage pharmaceutical company developing a new generation of orphan medicines to revolutionize the care of patients with liver and rare pediatric diseases. We address the unmet medical needs in emergency care. Our mission is to support acute decompensations of cirrhosis and to save infants born with rare genetic disorders. Hepatology, Hyperammonemia, Metabolic disease, Liver diseases, and Gastroenterology

35 similar entities Type: Startup Activities: biotech deeptech

Data analysis and in silico modelization solutions for genetic research and personalized medicine Expert in systems biology, VIDIUM brings data analysis and in silico modelization solutions for genetic research. We unlock the power of single-cell analysis to characterize and master the complexity of cell fate dynamics: "As Google did for urban networks, we built our navigation map in cellular genetic networks!" Guided by knowledge-driven approaches, we create highly representative digital twins from single-cell data, to make accurate predictions. These in silico avatars of genetic networks allows us to "find our way" through the billions of possible interactions between our 20,000 …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

An online platform for scientific partnering helping take discoveries from bench to bedside. Inpart is the leading platform for scientific partnering. We provide comprehensive solutions to initiate, optimize, and manage collaborations across industry and academia. In 2022, market-leading biopharma partnering platform Inova successfully merged with IN-PART, a specialized online matchmaking platform focused on fostering collaboration between academia and industry. ​ The strategic union of the two companies as Inpart now offers a powerful platform equipping teams across pharma, biotech, and academia with solutions to showcase innovations and technologies; find untapped science; identify new partners; accelerate deal-making; and manage collaborations. ​ …

41 similar entities Type: Startup Activities: biotech Technologies: SaaS

Leading biotechnology company who supports scientists worldwide with high-end human cell culture products and services. At PromoCell, we help scientists do better research with a world-class portfolio of human primary, stem and blood cells as well as optimized cell culture media. With over 35 years of expertise, we are recognized globally for supplying scientists with the tools and support they need to do groundbreaking research. All our products comply with European biomedical conventions, ensuring human rights and donor privacy are always protected. Our ISO certifications demonstrate our absolute commitment to quality and our EXCiPACTTM GMP certification enables us to produce …

141 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to science - Committed to your health The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organization active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 12,000 members from 124 countries, as well as 74 National Allergy Societies. EAACI’s mission is to promote basic and clinical research; to collect, assess and diffuse scientific information; to act …

49 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Restore health and save lives through innovative medicines Rostra strives urgently to bring novel medicines to patients and clinicians with the power to restore health and save lives globally. Through its novel technology platform, Rostra is developing medicines for infectious diseases with an initial focus on invasive fungal infections. Pharmaceutical Discovery & Drug Development and Infectious Disease

85 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Enhancing human life and shaping the future world by creating inclusive innovations to make a positive impact. 🏔 Explore beyond possible. 🦿 Enhancing human life and shaping the future world by creating inclusive innovations to make a positive impact. Product design, Medical devices, Innovation design engineering, Innovation, Parkinson's, Diabetes, Gait disorders, Data science, and Remote monitoring

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Leading the Microbiome revolution Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in …

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering personalized medicine in epigenetics Oryzon Genomics (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology/hematology. Founded in 2000 and headquartered in Barcelona, Spain, Oryzon brings together a highly experienced team accross Barcelona, Boston, and New Jersey. The Company’s clinical portfolio is built around two differentiated LSD1 inhibitors. Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials, with very promising efficacy signals in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented …

86 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Single-Molecule Analysis. Revolutionizing Medical Research. UNOMR AG, a techBio startup from ETH Zurich, is pioneering single-molecule protein sequencing through their innovative interface nanopore sensor, currently with a focus on site-specific posttranslational modification analysis. UNOMR's patented solution has far-reaching applications across healthcare, pharmaceutical development, and food science, offering a powerful new tool for therapeutic discovery and medical food product innovation. Driven by the vision of bringing advanced proteomics directly to the patient, UNOMR aims to catalyze the next breakthrough in precision medicine by making sophisticated protein analysis accessible.

60 similar entities Type: Startup Activities: deeptech it services Technologies: Synthetic Biology

Peptide Intelligence for Smarter Formulations Nature’s Most Powerful Peptides, Discovered by AI We use artificial intelligence to unlock cell-signaling peptide ingredients for your product formulations. Discovered by AI, validated by human clinical studies, ready for your innovations. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener and more efficacious. From what we eat, to what we apply to our skin. By translating nature’s wisdom into innovation, together, we can change the life of billions. Pure peptides, Peptide mixtures, Hydrolysates, Multi targeted peptides, Bioinformatics, Artificial intelligence for drug discovery, Peptide drugs, and …

141 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Revolutionise science with your knowledge The BioExpert Network, or BEN, is an exclusive network of experts in the sectors of health, biotechnology, life science and investment. Members have the opportunity to access and evaluate funding proposals for innovative research and development projects before anyone else, and help shape the future of life science and medicine. Proposals which receive the most positive evaluations, in terms of innovation, scientific validity, team and business potential have the opportunity to progress to a crowdfunding campaign with Capital Cell, the first online investment platform in Europe specialized in health and biotechnology. PhD level scientists, physicians, …

79 similar entities Type: Incubators & VCs Startup Activities: deeptech agritech biotech fintech healthtech Technologies: Synthetic Biology

Shape the Future with Momentum Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition and diagnostics company. Guardion offers a portfolio of science-based, clinically supported nutrition, medical foods, and supplements that support healthcare professionals, their patients, and consumers in achieving health goals. Guardion's commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. By applying the latest science, technology and research, Guardion has positioned itself to address the escalating demand for solutions that promise to improve life-diminishing health problems. Guardion is dedicated to …

57 similar entities Type: SMB Activities: biotech deeptech healthtech

Making the most innovative therapies possible for everyone. Medios is a leading specialty pharmaceutical company and pioneer of individual medicine. Together with pharmacies, doctors and pharmaceutical companies, we ensure a safe and reliable supply of medicines for complex and serious illnesses. As a pharmaceutical supplier and GMP manufacturer of patient-specific therapies, we connect all relevant players in the healthcare market in a strong network. In this way, we make it possible for specialized medicines to arrive exactly where they are needed. Our focus is on the production and provision of patient-specific therapies as well as an efficient supply structure for …

130 similar entities Type: Startup Activities: healthtech Technologies: Data Analytics

Better Biologics Through Chemistry Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Sustainable Platform for Specialty Pharma. As a globally operating company headquartered in Germany, CHEPLAPHARM has established a leading and sustainable platform for specialty pharma during the past two decades. We invest worldwide in well-established pharmaceutical brands which have been developed and introduced by research-based pharmaceutical companies. Our deep expertise in this field enables us to sustain the value of these brands for patients and the medical community. In this way we help the research-based pharmaceutical industry divest from older products so they can focus resources on innovation and new product pipelines. This is how we ACHIEVE MORE together. Specialty …

120 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

For every therapeutic challenge, we question traditional assumptions and find better solutions. VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBETTM Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with …

90 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Members of Medicines for Ireland supply the majority of medicines in Ireland to both the HSE and to patients directly Medicines for Ireland is an organisation founded and motivated by a strong desire to reform the way Ireland currently procures and supplies medicines. Many of the practices and approaches taken are no longer fit for purpose and are outdated. Achieving reform in this essential area of patient care is a core objective of our organisation. Email - info@medicinesforireland.ie Twitter - twitter.com/medicinesForIRL

38 similar entities Type: Startup Activities: biotech deeptech

Clinically actionable pharmacogenetics for personalized care. Abomics is a Finnish health technology company founded in 2013 by medical doctors that specializes in pharmacogenetics. We support healthcare professionals with pharmacogenetic solutions that enable precision medication. Pharmacogenetic testing helps identify more effective and safer medication and dosages, reducing trial-and-error prescribing and minimizing the risk of adverse drug reactions. Our solutions are designed to integrate seamlessly into clinical workflows bringing pharmacogenetic insights into everyday clinical decision-making. Built on scientific evidence and clinical expertise, we are a trusted partner to hospitals, laboratories, pharmaceutical companies, genomic service providers, and biobanks. Our PGx solutions: • Interpretation …

48 similar entities Type: Startup Activities: healthtech Technologies: SaaS

Treating the individual, not just the disease, through personalized and optimized dosing. We need to shift to a world where we treat the individual, not just the disease. Our inventions work in combination with medicine to deliver personalized, optimized dosing, to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Closed Loop Medicine is a TechBio company developing combination prescription drug + software products, with the aim of bringing forward the promise of precision care. Our proprietary technology platform facilitates personalized drug dose optimization through integration of medicines and software with patient-led digital experiences and closed …

85 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Laigo's SureTAC platform enables rapid therapy development for removal of disease-driving membrane proteins #laigobio Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs

146 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Alzforum, founded in 1996, is a free, dynamic, web-based scientific community dedicated to understanding Alzheimer's disease and related disorders. Our editorial priorities are as diverse as the needs of the research community. The website reports news on the latest scientific findings from basic research to clinical trials; maintains public databases of animal models, therapeutics, genetic risk factors, and biomarkers; and holds live discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer's disease. The Alzforum team of professional science writers and …

45 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

We invent for life! At MSD - known as Merck & Co., Inc. in the United States and Canada, headquartered in Rahway, New Jersey - we are united by our purpose of harnessing the potential of science to save and improve lives around the world. For more than 130 years, we have provided hope through the development of important medicines and vaccines. We aspire to be the world's leading biopharmaceutical research company and are currently at the forefront of research into innovative health solutions to advance the prevention and treatment of human and animal diseases. We foster a diverse and …

237 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Imaging life, protecting lives. Aurum Biosciences Ltd is a clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS). Follow-on indications include heart disease, oncology, inflammatory conditions, spinal cord injury, and dementia. Preclinical development has been completed in the lead indication (AIS) and approval has been granted to initiate clinical studies in acute stroke patients. Concurrently, Aurum is pursuing opportunities to develop its pipeline indications with a focus on inflammatory conditions and oncology.

72 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. See our LinkedIn community guidelines: https://bit.ly/4nAfOZp Idorsia privacy policy: https://www.idorsia.com/legal/privacy-policy

61 similar entities Type: Startup Activities: biotech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating biomedical research by connecting biopharmas with the right preclinical cancer models and CRO partners Repositive is committed to accelerating the development of precision cancer therapies to the clinic by working with biopharmas and Contract Research Organisations (CROs) to improve the predictivity of pre-clinical cancer research. Through its Cancer Models Scout service, Repositive is helping biopharmas to optimise their pre-clinical cancer projects by identifying the most suitable cancer models for their requirements from its world-leading database of over 8000 models, as well as via outreach to an extended network of CRO contacts. Repositive works to connect researchers with the right …

130 similar entities Type: Startup Activities: biotech it services deeptech Technologies: Synthetic Biology

Integrated CDMO & Consultancy | Cell & Gene Therapy Experts | From CMC Strategy to GMP Manufacturing & Facility Design eXmoor Pharma is the only integrated UK cell and gene therapy CDMO with consultancy expertise embedded at every stage of your journey, from early-phase strategy through GMP manufacturing to commercialisation. For over 20 years, we have provided specialised CMC consulting, process development, and GMP clinical manufacturing to more than 170 clients. Our industry-leading scientists and strategists help biotech and pharma companies accelerate innovation while reducing risk and costs. Our purpose-built process development and GMP manufacturing facility offers end-to-end solutions across …

168 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Enhance & Preserve Natural Hearing ! Acousia is a pioneer of novel medicines. Founded in 2012, the company’s experienced and entrepreneurial management team is committed to combating hearing loss. Thanks to its exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic and an ecosystem of experts and CROs, Acousia has made significant strides with its advanced small molecule drug candidates. Hearing Loss Treatment and Hearing Loss Drug Development

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bringing energy to life We are a Phase 3 ready clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Supporting people affected by leukaemia through information, support and advocacy Leukaemia Care is a UK charity supporting people affected by leukaemia, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). We provide trusted information, practical support and advocacy to help people navigate diagnosis, treatment and life beyond blood cancer. Our work is shaped by the lived experiences of patients and carers, alongside evidence and insight from healthcare professionals. We speak up on the issues that matter to people affected by leukaemia, working collaboratively with partners across health, research and the voluntary sector to improve care, understanding and outcomes. Our aim is simple: …

59 similar entities Type: SMB Activities: healthtech

AI-powered and patient-inspired. We accelerate the discovery and development of rare disease treatments. Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Discovering the relationships at the heart of biology to cure disease. We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select …

135 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

www.aukera-tx.com Aukera Therapeutics is a spin-off from the Biozentrum at the University of Basel, developing the first RAPTOR inhibitors for the treatment of mTORC1-related pathologies. We pair deep mTOR expertise with an AI-driven drug discovery engine built for complex and hard-to-drug targets. Our lead program focuses on rare neurological disorders such as Tuberous Sclerosis. Future applications of RAPTOR inhibitors include neurodegenerative, metabolic, and age-related diseases.

98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Building Extraordinary Lives® with proven, cutting-edge dietary supplements and skin care products. Cerule® is a biotech company that sells proven, one of a kind dietary supplements, skin care and wellness products. Our products are validated by years of scientific research and development, patents and published scientific papers. We challenge the status quo and are constantly striving to find and develop groundbreaking health solutions that produce positive changes to help you live a longer, healthier and happier life. It is with this mission that Cerule has been positively impacting countless lives worldwide for more than a decade. We believe the extraordinary …

61 similar entities Type: SMB Activities: biotech deeptech healthtech cosmetics Technologies: Synthetic Biology

Cutting-edge drugs for calcium-related diseases An innovative SME founded in December 2016 and committed to the discovery and development of orphan drugs for patients affected by calcium-related genetic diseases. ChemiCare’s mission is the improvement of the quality of life of patients affected by rare diseases such as Duchenne Muscular Dystrophy and Tubular Aggregate Myopathies, and autoimmune disorders by the development of a therapy that restores the abnormal intracellular calcium level, a common feature of these diseases. biotechnology, orphan disease, calcium-related disease, and rare disease

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially …

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 300+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer. Our products and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe. The Company considers its employees to be its most valuable asset and we are committed to providing opportunities for individuals to learn and grow as a means to further their professional development. MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees …

258 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Mereo BioPharma is a clinical-stage company focused on developing & commercialising rare disease & oncology treatments. Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused …

278 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating enzyme discovery and design through computer simulations Almost any industry can implement clean, sustainable and efficient processes using biocatalysts. It's just a matter of making these solutions accessible to everyone. 💡 At Zymvol, we’re on a mission to develop custom-made enzymes for any industry; turning green chemistry into the go-to option for companies worldwide. By combining physics-based simulations, AI, and real-world industrial data, Zymvol designs scale-ready enzymes faster, cheaper, and with higher predictability than traditional approaches. Get to know us better at: → www.zymvol.com Or grab a coffee ☕ with us: → info@zymvol.com . . . For more information …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Elevating the health and beauty of life GENEL is an international French biotech company that offers expert multi-disciplinary services to Dermo-Cosmetic, Nutraceutique and Pharmaceutical companies. We support our clients by identifying the right commercial strategy for the successful launch of their product. GENEL for Cosmetics, Dermo and Nutraceutique: Works hand in hand with you to build the unique story of each of your ingredients, and thus elevate the specialty and values of your brand. Thanks to more than 10 years expertise in Skin Homeostasis and in Functional Genomics, we specialize in assisting companies like you that are in the Dermo- …

140 similar entities Type: SMB Activities: deeptech biotech

Biotech specialized in the design of new medicine. Let's connect to know more about us ! At Aceso, we leverage our technology platform to explore new molecular pathways and develop strategic approaches aimed at redefining standards of care where existing therapies are insufficient. In the development of a new therapy for cystic fibrosis, Aceso is starting with ATC-101, its most advanced program designed to address the limitations of current treatments. Supported by robust proof-of-concept data and promising preclinical evidence, we are advancing toward IND-enabling studies, with entry into clinical trials as the next major milestone. With a science-driven roadmap and …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

FROM DISCOVERY TO THERAPEUTICS MT-act is a CNRS spin-off. #techtransfer We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the skeleton of the cells called microtubules - abbreviated MT. Stiffening of the skeleton of our cells is a central disease driver. That is why we act on them. We developed a technology platform to charter an entirely neglected pharmaceutical space. MT-act prioritizes indications based on scientific evidence, proven unmet medical needs and where the roadmap to patients is feasible and desired. Drug development, Microtubules, Tubulin code, Preclinical, Drug screening, first-in-class, and drug discovery

153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Drepacare is the first mobile application intended for #sickle cell patients. Sickle cell anemia is the most widespread genetic disease in the world; 50 million people are affected, including 12,000 in France. Created in 2016 by three entrepreneurs/students in a Master's degree in nutrition and public health in parallel with their careers as pharmacists, nurses and biotechnology engineers, it aims to make the daily lives of patients easier with features that help manage treatments, diet, the frequency of crises and hospitalizations. The idea starting from the observation of a great lack of communication and information on sickle cell anemia, this …

86 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Focused on the Few Social media guidelines: http://www.recordatirarediseases.com/social-media At Recordati Rare Diseases, we focus on the few - those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions. Social Media Guidelines: http://www.recordatirarediseases.com/social-media Rare Diseases, Orphan Drugs, Metabolic Diseases, Lysosomal Disorders, Rare Cancers, and Endocrinology

133 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

298 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A better health accessible to all patients Serious diseases and their impact on patients is what fuels our innovative approach to solving patients' unmet needs. We are leading a new way to treating cystic fibrosis and other disease in need of new solutions. Cystic Fibrosis, Bone Diseases, and Inflammatory Diseases

64 similar entities Type: Startup Activities: deeptech healthtech biotech

Bring solutions for rare disease and unmet needs with our medical knowledge base! MyDisease2EZ®, plateforme intelligente centrée sur les besoins des patients, leur maladie et, les solutions thérapeutiques associées. Notre technologie AI & Analytics permet de centraliser, simplifier, synthétiser, annoter chaque donnée pour les valoriser ! L’une de nos priorités est d’apporter des solutions pour les maladies rares, et les besoins médicaux non couvert. MyDisease2EZ®, an intelligent platform focused on patient needs, their disease, and the associated therapeutic solutions. Our Data technology uses artificial intelligence to centralize, simplify, synthesize, annotate each data to extract a value! One of our priorities …

65 similar entities Type: Startup Activities: healthtech Technologies: A.I.

Expert in protein-interaction discovery, target identification, induced proximity and single-domain antibodies/VHH. Who else knows your drug or protein better than you? Who else knows protein interactions better than us? Hybrigenics Services is a complete solution provider of cutting-edge technologies dedicated to the study of protein interactions and target identification for drugs. We are also proud to now offer a unique, proprietary nanobody selection service. We help researchers: - Understand proteins'​ functions through the elucidation of their interactions - Characterize precisely a known interaction (map critical domains or amino-acids...) - Identify the targets of small molecules of therapeutic interest - Decipher …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We make clinical approach rapid and easy Linking human metabolism to cell biology What: The methodology that we have developed within our academic laboratory makes it possible to quickly and directly obtain scientific data from humans to define the potential health benefit of a nutritional product, diversify and reposition an accredited drug or even search for and validate biomarkers of interest. Why: Created in March 2020, Clinic’n’Cell is a spin-off from our INRAe/University Clermont Auvergne academic laboratory which aims to simplify the obtaining of scientific data in humans to mark out your clinical investigations or simply boost your scientific marketing. …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Evidence-based drug repurposing platform CXS Therapeutics is a medtech platform involved in the screening and repurposing of therapeutic molecules in diseases affecting the CNS. The solutions are patient-centered. From a methodological point of view, the identification of treatments of interest comes from the use of transdisciplinary tools and a methodical exploration of bibliographic knowledge. The purpose? Offer treatments to patients with pathologies affecting the central nervous system where an unmet therapeutic need remains. Medtech, Parkinson's, Neurodegenerative Diseases, Treatments, Screening, Repurposing, Research, Innovation, Sciences, Brain, and Health

157 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We build foundation models that will transform biology. We use cutting-edge technology to transform multiscale data into actionable representations to fuel breakthrough discoveries. Join us on our mission to build foundation models that transform biology. artificial intelligence, biology, and foundation models

104 similar entities Type: Startup Activities: biotech it services Technologies: Generative A.I. A.I.

Creative Technologies for Efficient Therapeutics, Precision medicine Inoviem Scientific is a private Bioanalytical company which delivers enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. We reconcile translational pharmacology and human physiology by using fresh patient material from the target cohort, embracing the complexity of human diseases. Inoviem's enabling technologies are working in pathological conditions to get the treatment in development to the right patient. Our indication-agnostic access to patients combined with innovative label-free platforms deliver Target identification and validation, targets & Mode of Action deconvolution, patient stratification, …

196 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We produce customised chemical proteins to help our bio-pharms partners to accelerate their projects. 🧪 X’PROCHEM is a biotech company who invented an advanced and proprietary ligation technology. We help our bio-pharma partners design and create therapeutic, vaccine and diagnostic proteins. Unlike recombinant fermentation we can produce proteins containing up to 400 amino acids, without isoforms, endotoxins, or biological contaminants. We co develop solutions with our partners to understand the real needs within the context. By working closely, we can adapt to changing needs and circumstances. protein, purification, synthesis, protein production, peptide synthesis, and life sciences

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The color of medical innovation We are proud to present Bioprodig to you. Our student project dedicated to the production of low-cost prodigiosin, a prodigious pigment with multiple innovative medical applications. Our team of 8 enthusiasts is committed to bringing positive change to healthcare. Our vision: Transform medical research with an innovative pigment. We are looking for partners and sponsors to help us achieve our mission. Join us on this adventure to contribute to the fight against cancer and other diseases. Stay tuned to learn more about our project and the latest advances in the world of prodigiosin.

63 similar entities Type: Startup Activities: deeptech healthtech

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

171 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Improve the lives of children with CNS diseases Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children. Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen’s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers. Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Lilly unites caring with discovery to create medicines that make life better for people around the world. At Lilly, we make a difference for people the world over by discovering, developing, and delivering the breakthrough medicines that help them live longer, healthier more active lives. What’s more, you can also count on us and our people to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism and a creative and innovative can-do spirit. General Information and Guidelines: Eli Lilly and Company strives to create informative and engaging online communities that share information in meaningful ways. We welcome and encourage your …

46 similar entities Type: SMB Activities: healthtech

Make​ your Own Neuronal Network At MicroBrain Biotech, our mission is to revolutionize drug development by embracing ethical and cruelty-free practices, putting humanity at the center of our work, and relentlessly pursuing groundbreaking discoveries. We are committed to creating innovative solutions that improve the quality of life for patients and their families, while treating all living beings with compassion and respect. Through collaboration, scientific excellence, and a commitment to sustainability, we aim to leave a lasting positive impact on the world of healthcare and beyond.

143 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Engineering Biological Alpha Pheiron is an applied AI lab dedicated to Biological Alpha: the ability to know what biology will work in humans early enough to change the outcome of a drug program. We underwrite biology risk against clinical outcomes and use the edge to select and develop drug programs with the highest probability of success. At today's pace, humanity will wait 500 years for every known disease to have a cure. Twenty generations of patients. Pheiron compresses this timeline by radically increasing the drug-per-dollar output. 500 years is too long. We publish predictions on selected upcoming clinical readouts to …

70 similar entities Type: Startup Activities: healthtech it services Technologies: A.I.